Metformin and proton pump inhibitors have been implicated in decreasing levels of vitamin B~12~ independently. The purpose of this study was to evaluate the effect of concomitant use of metformin and proton pump inhibitors on the incidence of vitamin B~12~ deficiency.

A retrospective chart review was done using the computerized patient record system at the Memphis VA Medical Center for 614 patients with type 2 diabetes and previously collected vitamin B~12~ levels. Patients were excluded if they were over the age of 60 years; on a vegetarian diet; had been diagnosed with pernicious anemia, documented by a positive Schilling test or anti-intrinsic factor antibody, or pancreatic exocrine insufficiency; had undergone a gastrectomy or bowel resection; or had been treated with supplemental calcium, H2 blocker, or B~12~ within 3 months of data collection. The vitamin B~12~ levels were assessed using a competitive immunoassay with direct chemiluminescent technology. Deficiency was defined as vitamin B~12~ levels \<300 pg/mL. A χ^2^ test was used to compare patients taking metformin or proton pump inhibitors alone and those taking both with a control population taking neither medication.

Mean ± SD age was 65.08 ± 9.23 years, with a majority of male patients (96.3%). African Americans comprised 40.07% of the study population and Caucasians 50.33%; 9.6% had "other" listed for race. The incidence of vitamin B~12~ deficiency was found in 48 (22.2%) of the 216 control subjects. This was not significantly different compared with 32 (21.91%) of the 146 metformin subjects or 33 (25.58%) of the 129 proton pump inhibitor alone subjects (*P* = 0.9454 and 0.4763). However, there was a significant difference found in 42 (34.15%) of the 123 concomitant metformin and proton pump inhibitor subjects compared with the control group (*P* = 0.0096).

Metformin is a first-line medication used in the treatment of type 2 diabetes but has also been shown in multiple studies to reduce serum B~12~ levels in 10--30% of patients ([@B1]). Proton pump inhibitors are also commonly used medications for the treatment of gastroesophageal reflux disease and peptic ulcer prevention and treatment and, short-term, have been shown to decrease B~12~ levels from 3.4 to 0.4% (*P* \< 0.05) in a 2-week period ([@B2]). However, studies looking at long-term proton pump inhibitor use and vitamin B~12~ deficiency have yielded conflicting results ([@B3],[@B4]). Ting et al. ([@B5]) found no significantly increased risk for concurrent use of histamine H2 receptor antagonist or proton pump inhibitor in the development of metformin-related B~12~ deficiency. However, they did not separate out the use of H2 blockers from proton pump inhibitors in calculating the risk of developing metformin-related B~12~ deficiency.

Proton pump inhibitors and metformin alone were not associated with a significant difference in vitamin B~12~ deficiency, but the combination was associated with a significant increase in vitamin B~12~ deficiency. More studies are needed to elucidate the exact mechanisms by which proton pump inhibitors and metformin affect vitamin B~12~ levels and relate these changes to clinical findings.
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